miRNA-1226: As a Potential Diagnostic Marker in FFPE Tissue of Breast Cancer

Shayan Rasheed Abubakir

doi:10.21271/ZJPAS.38.2.3

Authors

Shayan Rasheed Abubakir Department of Biology, College of Education, Salahaddin University, Erbil, Kurdistan Region, Iraq

DOI:

https://doi.org/10.21271/ZJPAS.38.2.3

Keywords:

Breast Cancer, miR-1226, Diagnostic Biomarker

Abstract

Backgrounds: Researchers have just commenced the exploration of miRNAs as a prospective new class of biomarkers. This study investigates the potential of miR-1226 as a significant prognostic factor for BC. Methods: The miR-1226 expression was detected in 30 pairs of FFPE tissues using qRT-PCR. The clinicopathological characteristics of patients regarding miR-1226 expression, together with fold change analysis using the 2^-ΔΔCT method, were further investigated. All statistical analyses were performed with GraphPad and MedCalc. Results: We found that the miR-1226 level in BC FFPE tissues is slightly increased compared to control tissues. Also, we examined the relationship associated with clinicopathological features and miR-1226 expression levels of BC patients. This investigation revealed no significant association between miR-1226 expression levels and the clinical progression. Age, lymph node involvement, and Ki-67 expression had no significant correlation with outcome status. No significant relationships were observed between tumor-related factors such as grade and size. The hormone receptor status, PR status, and HER-2 status did not exhibit a significant correlation with outcome stratification. The trend regarding PR status may necessitate additional examination for its prognostic significance. Moreover, the p-value, AUC, and Std. Error, sensitivity, and specificity are (p < 0.006, 0.684,0.0723, 83.3, and 60, respectively), which signifies a moderate capacity of the test to differentiate between tumors and controls. The results of fold change analysis employing the 2^-ΔΔCT method indicated a (1)-fold elevation in miR-1226 expression in tumors relative to controls. Conclusions: We demonstrated that a slight elevation of miR-1226 expression correlates with the progression of BC, and this indicates that miR-1226 may possess an oncogenic function in BC tumorigenesis and progression.

References

CHAUHAN, S., MATHUR, R. & JHA, A. K. 2025. The Impact of microRNA SNPs on Breast Cancer: Potential Biomarkers for Disease Detection. Mol Biotechnol, 67, 845-861.

CHEN, X., TAN, W., LI, W., LI, W., ZHU, S., ZHONG, J., SHANG, C. & CHEN, Y. 2019. miR-1226-3p promotes sorafenib sensitivity of hepatocellular carcinoma via downregulation of DUSP4 expression. Journal of Cancer, 10, 2745.

ELSHIMY, R., EL-MAHDY, H. A., MANSOUR, O. A., BADR, M. & ALI, A. M. 2017. MiR-133a and MiR-155 as potential minimally invasive biomarkers in breast cancer. Cancer Biology, 7, 96-105.

HOUGHTON, S. C. & HANKINSON, S. E. 2021. Cancer progress and priorities: breast cancer. Cancer epidemiology, biomarkers & prevention, 30, 822-844.

HUSSEN, B. M., ABDULLAH, K. H., ABDULLAH, S. R., MAJEED, N. M., MOHAMADTAHR, S., RASUL, M. F., DONG, P., TAHERI, M. & SAMSAMI, M. 2023a. New insights of miRNA molecular mechanisms in breast cancer brain metastasis and therapeutic targets. Non-coding RNA Research, 8, 645-660.

HUSSEN, B. M., ABDULLAH, S. R., RASUL, M. F., JAWHAR, Z. H., FARAJ, G. S. H., KIANI, A. & TAHERI, M. 2023b. MiRNA-93: a novel signature in human disorders and drug resistance. Cell Communication and Signaling, 21, 79.

HUSSEN, B. M., RASUL, M. F., ABDULLAH, S. R., HIDAYAT, H. J., FARAJ, G. S. H., ALI, F. A., SALIHI, A., BANIAHMAD, A., GHAFOURI-FARD, S. & RAHMAN, M. 2023c. Targeting miRNA by CRISPR/Cas in cancer: advantages and challenges. Military Medical Research, 10, 32.

KAIDAR-PERSON, O., MEATTINI, I., BOERSMA, L. J., BECHERINI, C., CORTES, J., CURIGLIANO, G., DE AZAMBUJA, E., HARBECK, N., RUGO, H. S. & DEL MASTRO, L. 2024. Essential requirements for reporting radiation therapy in breast cancer clinical trials: An international multi-disciplinary consensus endorsed by the European Society for Radiotherapy and Oncology (ESTRO). Radiotherapy and Oncology, 195, 110060.

LIN, F. & LI, R. 2022. MiR-1226, mediated by ASCL1, suppresses the progression of non-small cell lung cancer by targeting FGF2. Bulletin du Cancer, 109, 424-435.

MA, Y., LU, Z., QIU, J., LUO, H., TANG, L., LI, Y. & LI, P. 2024. Symptom experience in endocrine therapy for breast cancer patients: A qualitative systematic review and meta-synthesis. Asia-Pacific Journal of Oncology Nursing, 11, 100364.

MAHMOUD, M. M., SANAD, E. F. & HAMDY, N. M. 2021. MicroRNAs’ role in the environment-related non-communicable diseases and link to multidrug resistance, regulation, or alteration. Environmental Science and Pollution Research, 28, 36984-37000.

MICHAELS, E., CHEN, N. & NANDA, R. 2024. The Role of Immunotherapy in Triple-Negative Breast Cancer (TNBC). Clinical Breast Cancer.

MOORE-PALHARES, D., CHEN, H., KHAN, B. M., MCCANN, C., BOSNIC, S., HAHN, E., SOLIMAN, H., CZARNOTA, G., KARAM, I. & RAKOVITCH, E. 2024. Locoregional ablative radiation therapy for patients with breast cancer unsuitable for surgical resection. Practical Radiation Oncology, 14, 316-327.

NAJJARY, S., MOHAMMADZADEH, R., MOKHTARZADEH, A., MOHAMMADI, A., KOJABAD, A. B. & BARADARAN, B. 2020. Role of miR-21 as an authentic oncogene in mediating drug resistance in breast cancer. Gene, 738, 144453.

NATARAJAN, L., PU, M., DAVIES, S. R., VICKERY, T. L., NELSON, S. H., PITTMAN, E., PARKER, B. A., ELLIS, M. J., FLATT, S. W., MARDIS, E. R., MARINAC, C. R., PIERCE, J. P. & MESSER, K. 2019. miRNAs and Long-term Breast Cancer Survival: Evidence from the WHEL Study. Cancer Epidemiol Biomarkers Prev, 28, 1525-1533.

NURZADEH, M., NAEMI, M. & SHEIKH HASANI, S. 2021. A comprehensive review on oncogenic miRNAs in breast cancer. Journal of Genetics, 100, 1-21.

OTMANI, K. & LEWALLE, P. 2021. Tumor suppressor miRNA in cancer cells and the tumor microenvironment: mechanism of deregulation and clinical implications. Frontiers in oncology, 11, 708765.

SHARMA, S., OPYRCHAL, M. & LU, X. 2022. Harnessing tumorous flaws for immune supremacy: is miRNA-155 the weak link in breast cancer progression? J Clin Invest, 132.

SIEGEL, R. L., MILLER, K. D., WAGLE, N. S. & JEMAL, A. 2023. Cancer statistics, 2023. CA: a cancer journal for clinicians, 73, 17-48.

SVORONOS, A. A., ENGELMAN, D. M. & SLACK, F. J. 2016. OncomiR or tumor suppressor? The duplicity of microRNAs in cancer. Cancer research, 76, 3666-3670.

VAN SCHOONEVELD, E., WILDIERS, H., VERGOTE, I., VERMEULEN, P. B., DIRIX, L. Y. & VAN LAERE, S. J. 2015. Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management. Breast Cancer Res, 17, 21.

WANG, C., WANG, J., CUI, W., LIU, Y., ZHOU, H., WANG, Y., CHEN, X., CHEN, X. & WANG, Z. 2021. Serum exosomal miRNA-1226 as potential biomarker of pancreatic ductal adenocarcinoma. OncoTargets and therapy, 1441-1451.

WANG, H., TAN, G., DONG, L., CHENG, L., LI, K., WANG, Z. & LUO, H. 2012. Circulating MiR-125b as a marker predicting chemoresistance in breast cancer. PloS one, 7, e34210.

YADAV, P., MIRZA, M., NANDI, K., JAIN, S., KAZA, R., KHURANA, N., RAY, P. & SAXENA, A. 2016. Serum microRNA-21 expression as a prognostic and therapeutic biomarker for breast cancer patients. Tumor Biology, 37, 15275-15282.

ZHANG, X., CONG, L., YU, R., YU, Q., HOU, X. & ZHOU, Y. 2025. MicroRNA‑96 promotes the proliferation and migration of breast cancer cells by inhibiting Smad7 expression. Oncology Letters, 29, 151.

ZHANG, X., LIU, J., JI, M., QI, G. & QIAO, R. 2024. Long noncoding RNA GUSBP11 knockdown alleviates nasopharyngeal carcinoma via regulating miR-1226-3p/TM9SF4 Axis. Cancer Biotherapy & Radiopharmaceuticals, 39, 133-143.

ZHANG, Z., ZHANG, L., YU, G., SUN, Z., WANG, T., TIAN, X., DUAN, X. & ZHANG, C. 2020. Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer. Cancer chemotherapy and pharmacology, 86, 761-772.